Anti-CD274 (PD-L1) Antibody Pipeline Insight Report, 2018 Edition - ResearchAndMarkets.com

The "Anti-CD274 (PD-L1) Antibody - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Anti-CD274 (PD-L1) Antibody - Pipeline Insight, 2018 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD274 (PD-L1) Antibody development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Anti-CD274 (PD-L1) Antibody - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Anti-CD274 (PD-L1) Antibody

The report assesses the active Anti-CD274 (PD-L1) Antibody pipeline products by developmental stage, product type, molecule type, and administration route.

Key Topics Covered:

1. Report Introduction

2. Overview

3. Pipeline Therapeutics

• An Overview of Pipeline Products

4. Comparative Analysis

5. Pipeline Products in Clinical Stages

• Product Description
• Research and Development
• Product Development Activities

6. Pipeline Products in Non-clinical Stages

• Product Description
• Research and Development
• Product Development Activities

7. Therapeutic Assessment: Active Products

• Pipeline Assessment by Route of Administration
• Pipeline Assessment by Stage and Route of Administration
• Pipeline Assessment by Molecule Type
• Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

• Product Description
• Research and Development
• Product Development Activities
• Reason for dormancy/discontinuation

Companies Mentioned

• Genentech
• MedImmune
• Merck KGaA
• Alphamab
• CytomX Therapeutics
• EMD Serono
• Aurigene Discovery Technologies
• Eli Lilly
• Novartis Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wdwf4c/anticd274?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181219005720/en/